Judging Obesity Drugs: Can Patient-Focused Statistics Bring Simplicity, Clarity?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The odds ratio would be a simpler way to look at an obesity drug’s success in promoting 5% weight loss than the current three-step process, FDA’s statistical reviewer said in her assessment of Belviq’s efficacy.